<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787276</url>
  </required_header>
  <id_info>
    <org_study_id>HepEN</org_study_id>
    <nct_id>NCT04787276</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy</brief_title>
  <official_title>Probiotic E.Coli Nissle 1917 Comparing to Lactulose and Rifaximin in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bogomolets National Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bogomolets National Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of study to assess the short-term efficacy and safety of probiotic E.coli Nissle&#xD;
      1917 strain comparing to lactulose and rifaximin in patients with mild (Stage 1-2) or minimal&#xD;
      hepatic encephalopathy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2017</start_date>
  <completion_date type="Actual">March 15, 2020</completion_date>
  <primary_completion_date type="Actual">January 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Stroop test</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum ammonia</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum inflammatory cytokine</measure>
    <time_frame>1 month</time_frame>
    <description>The level of IL-6, IL-8 and INFγ in pg / ml will be assesed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteriology measured in the stool flora by specialized non-culture techniques</measure>
    <time_frame>1 month</time_frame>
    <description>The percentage of patients in each group were evaluated and characterized by a decrease below the normal content of symbiotic bacteria Bifidobacterium (less than 107 CFU / g), lactobacilli (less than 107 CFU / d), E.coli with normal properties (less than 106 CFU / d) and increase in content E.coli with altered properties (more than 106 CFU / g), pathogenic enterobacteria (not normally detected) and fungi of the genus Candida (more than 104 CFU / d)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Liver Cirrhosis</condition>
  <condition>End Stage Liver DIsease</condition>
  <arm_group>
    <arm_group_label>E.coli Nissle 1917</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>probiotic, oral, for the first 4 days, 1 capsule, and then 2 capsules per day for 1 month treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactulose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifaximin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rifaximin, oral, 500 mg BID, 1 months of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>E.coli Nissle 1917</intervention_name>
    <description>Probiotic contains biomass of E.coli Nissle 1917, 2,5-25·109 colony forming units - CFU/g</description>
    <arm_group_label>E.coli Nissle 1917</arm_group_label>
    <other_name>MUTAFLOR capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment</description>
    <arm_group_label>Lactulose</arm_group_label>
    <other_name>DUPHALAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>rifaximin, oral, 500 mg BID, 1 months of treatment</description>
    <arm_group_label>Rifaximin</arm_group_label>
    <other_name>Alfa Normix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cirrhosis diagnosed on the basis of liver biopsy, liver stiffness measurement or&#xD;
             radiological study;&#xD;
&#xD;
          -  presence of minimal or mild (Grade 1-2) HE as defined by West Haven criteria;&#xD;
&#xD;
          -  two or more documented episodes of HE in the last 6 months, in addition to at least&#xD;
             one episode in the last 3 months;&#xD;
&#xD;
          -  subject is capable and willing to comply with all study procedures;&#xD;
&#xD;
          -  signed inform consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of taking L-ornithine- L -aspartate, zinc, metronidazole, or neomycin,&#xD;
             antibiotics, probiotics and yogurt consumption within 6 weeks;&#xD;
&#xD;
          -  subject has a history of allergy or intolerance to lactulose and/or rifaximin;&#xD;
&#xD;
          -  alcohol intake during the past 6 month or during follow up;&#xD;
&#xD;
          -  recent (6 weeks) gastro-intestinal bleed;&#xD;
&#xD;
          -  hepato-cellular carcinoma or liver transplantation;&#xD;
&#xD;
          -  renal insufficiency;&#xD;
&#xD;
          -  significant comorbid illness such as heart or respiratory failure;&#xD;
&#xD;
          -  concurrent infection such as spontaneous bacterial peritonitis, pneumonia or urinary&#xD;
             tract infection;&#xD;
&#xD;
          -  any neurologic diseases such as alzheimer's disease, parkinson's disease and&#xD;
             nonhepatic metabolic encephalopathies;&#xD;
&#xD;
          -  subject has any condition or circumstance that would, in the opinion of the&#xD;
             Investigator, prevent completion of the study or interfere with analysis of study&#xD;
             results, including history of noncompliance with treatments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elina Manzhalii, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bogomolets National Medical University</affiliation>
  </overall_official>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bogomolets National Medical University</investigator_affiliation>
    <investigator_full_name>Nazarii Kobyliak</investigator_full_name>
    <investigator_title>Associate Professor, Endocrinology Department</investigator_title>
  </responsible_party>
  <keyword>hepatic encephalopathy</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>End Stage Liver DIsease</keyword>
  <keyword>E.coli Nissle 1917</keyword>
  <keyword>Probiotic</keyword>
  <keyword>lactulose</keyword>
  <keyword>rifaximin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

